Announcement
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference
Theravance Biopharma
PR-12-24-NI-137Dec 17, 2024
COVID-19 Lung Injury
Theravance Biopharma Doses First Patients with Acute Lung Injury Caused by COVID-19
Theravance Biopharma
PR-M04-20-NI-035Apr 24, 2020
Study Results
Theravance Biopharma Announces Ampreloxetine (TD-9855) Phase 2 Study Results Selected for Oral Presentation at 32nd European Neurology Congress
Theravance Biopharma, Inc.
PR-M03-19-NI-078Mar 27, 2019
Clinical Trials
Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis
Theravance Biopharma, Inc.
PR-M03-19-NI-035Mar 13, 2019
Realignment
Theravance Biopharma Announces Alignment of Workforce with Focus on Key Strategic Priorities
Theravance Biopharma
PR-M01-19-NI-024Jan 09, 2019
Respiratory
Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor
Theravance Biopharma
PR-M11-18-NI-102Nov 29, 2018
Crohn's Disease
Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease
Theravance Biopharma
PR-M11-18-NI-092Nov 27, 2018
Announcement
Theravance Biopharma to Present at the Credit Suisse 27th Annual Healthcare Conference
Theravance Biopharma
PR-M11-18-NI-043Nov 13, 2018
Clinical Data
Theravance Biopharma and Mylan to Present New Data from Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting
Mylan
PR-M10-18-NI-038Oct 11, 2018
Clinical Results
Theravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
Theravance Biopharma
PR-M08-18-NI-031Aug 09, 2018
Drug Development
Mylan and Theravance Will Receive FDA Decision on COPD Drug by November
Guy Tiene
Nice Insight
PAO-M02-18-NI-006Feb 06, 2018
New Drug Application
Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
Theravance Biopharma
PR-M02-18-NI-005Feb 01, 2018